Business Updates

IsoPet.com Reports Stronger Search Visibility and Increased Pet Owner Engagement in 2026

Expanded organic and AI search visibility supports growing awareness of IsoPet’s Precision Radionuclide Therapy™ (PRnT) for animal cancer treatment.

Kennewick, WA – October 16, 2026 – Vivos Inc. (OTCQB: RDGL) reported continued improvements in the online visibility of the IsoPet.com platform throughout 2026, reflecting the company’s ongoing efforts to expand awareness of IsoPet® Precision Radionuclide Therapy™ (PRnT) for cancer in companion and exotic animals. Stronger organic search performance has coincided with increased pet owner inquiries and growing interest in the company’s veterinary treatment network.

Throughout 2026, IsoPet.com demonstrated measurable improvements in organic search visibility across a broad range of animal cancer treatment topics, with some of the strongest results occurring during the second half of the year. The website achieved stronger Google search rankings across multiple treatment-related categories, expanding its visibility for searches involving canine, feline, equine, and exotic animal cancer care.

IsoPet.com’s organic search audience more than doubled between January and September 2026, with active users increasing approximately 114%, according to Google Analytics 4 data. This growth reflects a measurable expansion in the website’s organic reach during the period. Educational content covering animal cancer treatment options, veterinary treatment centers, and IsoPet’s approach has also attracted growing interest.

In addition to traditional search engines, IsoPet.com gained more visibility in AI-powered search results during 2026, encouragingly appearing in AI-generated responses addressing relevant animal cancer treatment topics.

PixelRank, the digital agency responsible for IsoPet.com’s website design and ongoing SEO strategy, has supported these improvements through website optimization and initiatives focused on strengthening visibility across traditional and AI-powered search platforms.

The improvements in online visibility have occurred alongside increased engagement from pet owners seeking information about IsoPet’s treatment options. Contact form submissions increased throughout the summer and reached their highest reported levels in September 2026, reflecting growing interest in the company’s veterinary treatment network.

Vivos also reported an increase in the number of animals treated with IsoPet® Precision Radionuclide Therapy™ (PRnT) during 2026.

The company continues to take a measured approach to IsoPet® marketing, balancing efforts to expand awareness and accessibility with operational priorities. This strategy is intended to support continued development of its APEL production facility and ongoing cost improvement initiatives as demand evolves.

“Pet owners looking for cancer treatment options are finding IsoPet® more easily, and we’re seeing increased engagement with our treatment network,” said Brad Weeks, President of Vivos Inc. “Our goal is to make this targeted therapy easier to understand and access while maintaining a measured approach to expansion. The progress we’ve made in online visibility supports our broader efforts to increase awareness of IsoPet® as our production capabilities continue to develop.”

IsoPet® Precision Radionuclide Therapy™ (PRnT) is designed to deliver a therapeutic radiation dose directly to a tumor while limiting exposure to surrounding healthy tissue. It is available for dogs, cats, horses, and exotic animals through a network of veterinary treatment centers.

About Vivos Inc.

Vivos Inc. is developing advanced Yttrium-90 based brachytherapy devices for the treatment of tumors in both animals (IsoPet®) and humans (RadioGel®). The Company is committed to delivering safer, more effective, and accessible cancer therapies through Precision Radionuclide Therapy™ (PRnT).

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of applicable federal securities laws. These statements include, but are not limited to, expectations regarding the continued growth of IsoPet® brand awareness, website visibility, pet owner engagement, treatment demand, veterinary treatment network expansion, production capabilities, and future business development. Actual results may differ materially from those expressed or implied due to various risks and uncertainties. Such factors include, among others, changes in market demand, competition, regulatory requirements, operational and production challenges, the effectiveness of marketing initiatives, and the Company’s ability to execute its business strategy.

Historical website traffic, search engine rankings, and engagement metrics are not necessarily indicative of future performance, treatment volumes, or revenue growth. Vivos Inc. undertakes no obligation to publicly update or revise any forward-looking statements, except as required by applicable law. Investors are encouraged to review the Company’s filings with the U.S. Securities and Exchange Commission for additional information regarding risks and uncertainties.

About the Author:

Next Post
Vivos Inc. Business Update: Progress on the Mayo Clinic Clinical Trial for RadioGel
Previous Post
September 2026 Highlights
keyboard_arrow_up